Intranasal and Intramuscular Immunization with Outer Membrane Vesicles from Serogroup C Meningococci Induced Functional Antibodies and Immunologic Memory release_3kz7qtiqhfc4tjodyetyy4naai

by Amanda Izeli Portilho, Victor Araujo Correa, Cinthya dos Santos Cirqueira, Elizabeth De Gaspari

Published in figshare.com by Taylor & Francis.

2022  

Abstract

Immunization is the key to prevent invasive meningococcal disease (IMD), caused by <i>Neisseria meningitidis</i>. Outer membrane vesicles (OMVs) can be used as meningococcal antigens. Isogenic mice A/Sn (H2<sup>a</sup>) were immunized with low antigenic doses of OMVs of an <i>N. meningitidis</i> C:2a:P1.5 strain, via intranasal/intramuscular route, adjuvanted by cholera toxin subunit B (CTB) or via intramuscular route only, adjuvanted by aluminium hydroxide (AH). Mice were followed until old age and humoral and cellular responses were assessed by ELISA, Immunoblotting, Dot-blot, Serum-bactericidal assay, Immunohistochemistry and ELISpot. OMV+CTB and OMV+AH groups presented statistically higher antibodies titers, which persisted until middle and old ages. IgG isotypes point to a Th2 type of response. Avidity indexes were considered high, regardless of adjuvant use, but only groups immunized with OMVs and adjuvants (OMV+CTB and OMV+AH) presented bactericidal activity. The antibodies recognized antigens of molecular weights attributed to porin and cross-reactivity proteins. Although the spleen of old mice did not present differences in immunohistochemistry marking of CD68+, CD4+, CD79+ and CD25+ cells, splenocytes of immune groups secreted IL-4 and IL-17 when stimulated with OMVs and meningococcal C polysaccharide. We concluded that both adjuvants, CTB and AH, improved the immunogenicity of low doses of OMVs and contributed to a persistent immune response. Even though AH is well established in the vaccinology area, CTB seems to be a promising adjuvant candidate for meningococcal vaccines: it is suitable for mucosal delivery and supports a Th2 type of response. Therefore, OMVs are still a relevant vaccine platform.
In text/plain format

Archived Files and Locations

application/pdf  13.0 MB
file_ynyhm2i75fckfmiopc5djhqvja
s3-eu-west-1.amazonaws.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-08-15
Version   v1
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 6fac5999-053a-48db-a047-b41345095a9e
API URL: JSON